GRAIL Inc. (GRAL)
NASDAQ: GRAL · Services-Medical Laboratories · Sunnyvale, CA
Our rating: Cautious
Cautious reaffirmed at $124.74, high conviction, November 10, 2026.
Breaks if: The Cautious call turns wrong if the November 2026 patent invalidation is fully reversed on appeal and GRAIL reports two consecutive quarters of revenue growth above 30% year-over-year within the following 12 months — both conditions together would signal the IP risk has cleared and commercial momentum is genuine enough to begin compressing the revenue multiple toward something defensible.
Key figures
| Market value | $4.5B |
|---|---|
| Revenue, last 12 months | $167M |
| Net income, last 12 months | −$406M |
| Free cash flow, last 12 months | −$312M |
| Price to earnings | n/a |
| Free cash flow yield | −7.0% |
| Dividend yield | 0.0% |
| Operating margin | −347.3% |
| Return on equity | −17.3% |
| Beta to the S&P 500 | 2.36 |
| Volatility, annualized | 104.1% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $38M | 3.7% | $-2.21 | −$79M |
| June 30, 2026 | $45M | 25.7% | $-2.56 | −$81M |
| March 31, 2026 | $41M | 28.1% | $-2.29 | −$87M |
| December 31, 2025 | $44M | 14.0% | $-2.38 | −$64M |
| September 30, 2025 | $36M | 26.3% | $-2.46 | −$64M |
| June 30, 2025 | $36M | 11.2% | $-3.18 | −$77M |
| March 31, 2025 | $32M | 19.1% | $-3.10 | −$95M |
| December 31, 2024 | $38M | 26.1% | $-1.93 | −$94M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.05B: Claude 35%, Gemini 20%, Mistral 12%
- Diluted earnings per share are above zero: Claude 2%, Gemini 5%, Mistral 2%
- Free cash flow for the quarter is above zero: Claude 4%, Gemini 5%, Mistral 5%
39 ledger entries and 10 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.